says heart drug darapladib fails in second late-stage trial
Send a link to a friend
[May 13, 2014]
— GlaxoSmithKline said its drug darapladib had not reduced
heart attacks or other major events in patients with acute coronary
syndrome, marking another disappointment for the innovative heart
Darapladib had already failed in a late-stage trial
for patients with well-treated heart disease. [ID:nL1N0MR078]
Patrick Vallance, GSK’s President of Pharmaceuticals R&D, said he
was disappointed that the outcome of the second phase III study did
not support a regulatory submission.
"In the study, darapladib did not achieve the primary endpoint of a
reduction of major coronary events versus placebo when added to
standard of care," the British company said on Tuesday.
(Reporting by Paul Sandle; editing by Kate Holton)
[to top of second column]
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.